Eric J. Lowe
Expertise in
11
conditions

Dr. Eric J. Lowe

Hematology | Pediatrics
601 Childrens Lane, 
Norfolk, VA 
Clinical Trials:Currently Recruiting for 4 Trials
Accepting New Patients
Offers Telehealth
Expertise in
11
conditions
601 Childrens Lane, 
Norfolk, VA 

Overview

Eric Lowe is a Hematologist and a Pediatrics provider practicing medicine in Norfolk, Virginia.

Dr. Lowe is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Anaplastic Large Cell Lymphoma, Non-Hodgkin Lymphoma, T-Cell Lymphoma, Langerhans Cell Histiocytosis, and Bone Marrow Aspiration.

Dr. Lowe is board certified in American Board Of Pediatrics - Pediatrics - 2027 and American Board Of Pediatrics - Pediatrics, Pediatric Hematology-Oncology - 2027. He is actively involved in clinical research, co-authoring 20 peer reviewed articles and participating in 91 clinical trials. Dr. Lowe is currently accepting new patients.

Specialties

Hematology
Pediatrics

Licenses

Pediatrics in VA

Board Certifications

American Board Of Pediatrics - Pediatrics - 2027
American Board Of Pediatrics - Pediatrics, Pediatric Hematology-Oncology - 2027

Fellowships

St. Jude Children's Research Hospital - 2004

Hospital Affiliations

SQCN Provider

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthKeepers
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

Children's Specialty Group Hematology and Oncology
601 Childrens Lane, Norfolk, VA 23507

Additional Areas of Focus

Dr. Lowe has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

90 Clinical Trials

A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Drug, Procedure, Radiation
Study Drug: Selinexor
Study Phase: Phase 1/Phase 2
A Study Using Molecular Guided Therapy With Induction Chemotherapy Followed by a Randomized Controlled Trial of Standard Immunotherapy With or Without DFMO Followed by DFMO Maintenance for Newly Diagnosed High-Risk Neuroblastoma
A Study Using Molecular Guided Therapy With Induction Chemotherapy Followed by a Randomized Controlled Trial of Standard Immunotherapy With or Without DFMO Followed by DFMO Maintenance for Newly Diagnosed High-Risk Neuroblastoma
Enrollment Status: Recruiting
Publish Date: September 04, 2026
Intervention Type: Drug
Study Drugs: Ceritinib, Dasatinib, Sorafenib, Vorinostat, DFMO
Study Phase: Phase 2
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
Enrollment Status: Recruiting
Publish Date: September 03, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Carboplatin, Selumetinib Sulfate, Vincristine Sulfate
Study Phase: Phase 3
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC# 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC# 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse
Enrollment Status: Recruiting
Publish Date: September 01, 2026
Intervention Type: Procedure, Drug, Radiation, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Hydrocortisone Sodium Succinate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Nivolumab, Pegaspargase, Thioguanine, Vincristine Sulfate
Study Phase: Phase 2
NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2026
Intervention Type: Drug
Study Drug: Difluoromethylornithine (DFMO)
Study Phase: Phase 2
Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2026
Intervention Type: Drug
Study Drug: Eflornithine
Study Phase: Phase 2
A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Biological
Study Drugs: Axitinib, Nivolumab
Study Phase: Phase 2
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Other
Study Drugs: Cabozantinib, Cabozantinib-S-Malate
Study Phase: Phase 2
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Radiation, Drug, Biological, Other
Study Drugs: Cyclophosphamide, Dactinomycin, Irinotecan hydrochloride, Temsirolimus, Vincristine sulfate, Vinorelbine
Study Phase: Phase 3
View 6 Less Clinical Trials

20 Total Publications

Bortezomib and vorinostat in combination with mitoxantrone, dexamethasone, and pegasparaginase during induction and reinduction for infants with acute lymphoblastic leukaemia: a multicentre single-arm phase 1/2 study.
Bortezomib and vorinostat in combination with mitoxantrone, dexamethasone, and pegasparaginase during induction and reinduction for infants with acute lymphoblastic leukaemia: a multicentre single-arm phase 1/2 study.
Journal: The Lancet. Haematology
Published: July 03, 2025
Similar Doctors
Expertise in
40
conditions
Expertise in
40
conditions
Referral may be required

Mayo Clinic-Rochester

5716 Cleveland St Ste 200, 
Virginia Beach, VA 
 (8.5 miles away)
507-284-2511
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mrinal Patnaik is a Hematologist practicing medicine in Virginia Beach, Virginia. Dr. Patnaik is highly rated in 40 conditions, according to our data. His clinical expertise encompasses Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Patnaik is currently accepting new patients.

Expertise in
21
conditions
Expertise in
21
conditions
Referral may be required

Mayo Clinic-Rochester

5716 Cleveland St Ste 200, 
Virginia Beach, VA 
 (8.5 miles away)
507-284-2511
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Animesh Pardanani is a Hematologist practicing medicine in Virginia Beach, Virginia. Dr. Pardanani is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Myelofibrosis, Systemic Mastocytosis, Essential Thrombocythemia, Splenectomy, and Bone Marrow Aspiration. Dr. Pardanani is currently accepting new patients.

Expertise in
17
conditions
Dr. Gaurav Goyal
Hematology
Expertise in
17
conditions
Dr. Gaurav Goyal
Hematology
Referral may be required

Mayo Clinic-Rochester

5716 Cleveland St Ste 200, 
Virginia Beach, VA 
 (8.5 miles away)
507-284-2511
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Gaurav Goyal is a Hematologist practicing medicine in Virginia Beach, Virginia. Dr. Goyal is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Histiocytosis, Reticulohistiocytoma, Non-Langerhans-Cell Histiocytosis, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Goyal is currently accepting new patients.

Frequently Asked Questions about Dr. Eric J. Lowe

How do I make an appointment with Dr. Eric J. Lowe?

You can book an appointment with Dr. Eric J. Lowe by calling their office at 757-668-7243. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Eric J. Lowe a top-rated expert for Anaplastic Large Cell Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Eric J. Lowe is classified as an Distinguished expert for Anaplastic Large Cell Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Eric J. Lowe specialize in?

While Dr. Eric J. Lowe is a Hematology, they have specific expertise in Anaplastic Large Cell Lymphoma, Non-Hodgkin Lymphoma, and T-Cell Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Eric J. Lowe participate in research or clinical trials?

Yes. Dr. Eric J. Lowe has published 20 articles and abstracts on conditions like Anaplastic Large Cell Lymphoma. You can view a list of Dr. Eric J. Lowe's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Eric J. Lowe accept my insurance?

Dr. Eric J. Lowe accepts most major insurance plans, including Anthem BCBS and Blue Cross Blue Shield. We recommend calling the office directly at 757-668-7243 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lowe's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 16 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile